Phase III study of Conmana shows benefits for NSCLC
A randomised, double-blind, Phase III non-inferiority trial of 400 patients with advanced Non-Small-Cell Lung Cancer showed that Conmana (icotinib), from Zhejang Beta Pharma, was non-inferior to gefitinib in terms of progression-free survival (median progression-free survival 4�6 months vs 3�4 months). The most common adverse events were rash (41% in the icotinib group vs 49% in the gefitinib group) and diarrhoea (22% vs 29%).
Conmana was approved in China in June 2011. Results were published in The Lancet: "Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind Phase 3 non-inferiority trial." Yuankai Shi et al. The Lancet Oncology, 13 August 2013 doi:10.1016/S1470-2045(13)70355-3